RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer.
Anna LinderKarin LarssonKarin WelénJan-Erik DamberPublished in: The Prostate (2020)
High levels of RGS2 are associated with aggressive forms of castration-resistant PC. The results demonstrate that a high level of RGS2 is associated with poor prognosis in association with castration-resistant PC growth. RGS2 alone, or in association with PSA, has the potential to identify patients that require additional treatment at an early stage during ADT.
Keyphrases
- poor prognosis
- early stage
- end stage renal disease
- long non coding rna
- prostate cancer
- newly diagnosed
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- papillary thyroid
- squamous cell carcinoma
- young adults
- radiation therapy
- lymph node
- free survival
- human health
- risk assessment
- squamous cell
- combination therapy
- neoadjuvant chemotherapy
- childhood cancer